ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the
efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib
in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal
growth factor receptor EGFR-activating mutation (s). Analyses of primary objective
(Progression Free Survival) will be done as defined in the protocol.